WO2000020024A3 - Procedes pour traiter les troubles non thyroidiens - Google Patents

Procedes pour traiter les troubles non thyroidiens Download PDF

Info

Publication number
WO2000020024A3
WO2000020024A3 PCT/US1999/022761 US9922761W WO0020024A3 WO 2000020024 A3 WO2000020024 A3 WO 2000020024A3 US 9922761 W US9922761 W US 9922761W WO 0020024 A3 WO0020024 A3 WO 0020024A3
Authority
WO
WIPO (PCT)
Prior art keywords
disorders
thyroid
igf
treatment
methods
Prior art date
Application number
PCT/US1999/022761
Other languages
English (en)
Other versions
WO2000020024A2 (fr
Inventor
Desmond Mascarenhas
Original Assignee
Celtrix Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celtrix Pharma filed Critical Celtrix Pharma
Priority to JP2000573383A priority Critical patent/JP2002526417A/ja
Priority to EP99951681A priority patent/EP1117425A2/fr
Priority to CA002345642A priority patent/CA2345642A1/fr
Priority to AU64070/99A priority patent/AU6407099A/en
Publication of WO2000020024A2 publication Critical patent/WO2000020024A2/fr
Publication of WO2000020024A3 publication Critical patent/WO2000020024A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des procédés permettant de traiter les troubles non thyroïdiens qui répondent à IGF, à IGFBP-3, ou qui sont indépendants de IGF. Les agonistes du tronc thyro-cervical et IGF sont administrés à des sujets souffrant de troubles non thyroïdiens répondant à IGF, afin d'atténuer les symptômes de ces troubles. Les antagonistes du tronc thyro-cervical et IGFBP-3 sont administrés à des sujets souffrant de troubles non thyroïdiens répondant à IGFBP-3, afin d'atténuer les symptômes de ces troubles. Enfin, les antagonistes du tronc thyro-cervical sont administrés aux sujets souffrant de troubles non thyroïdiens dépendants de IGF, afin d'atténuer les symptômes de ces troubles.
PCT/US1999/022761 1998-10-02 1999-09-29 Procedes pour traiter les troubles non thyroidiens WO2000020024A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2000573383A JP2002526417A (ja) 1998-10-02 1999-09-29 非甲状腺性疾患の治療方法
EP99951681A EP1117425A2 (fr) 1998-10-02 1999-09-29 Procedes pour traiter les troubles non thyroidiens
CA002345642A CA2345642A1 (fr) 1998-10-02 1999-09-29 Procedes pour traiter les troubles non thyroidiens
AU64070/99A AU6407099A (en) 1998-10-02 1999-09-29 Methods for the treatment of non-thyroid disorders

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US10279098P 1998-10-02 1998-10-02
US39913499A 1999-09-20 1999-09-20
US09/399,134 1999-09-20
US60/102,790 1999-09-20

Publications (2)

Publication Number Publication Date
WO2000020024A2 WO2000020024A2 (fr) 2000-04-13
WO2000020024A3 true WO2000020024A3 (fr) 2000-07-06

Family

ID=26799734

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/022761 WO2000020024A2 (fr) 1998-10-02 1999-09-29 Procedes pour traiter les troubles non thyroidiens

Country Status (5)

Country Link
EP (1) EP1117425A2 (fr)
JP (1) JP2002526417A (fr)
AU (1) AU6407099A (fr)
CA (1) CA2345642A1 (fr)
WO (1) WO2000020024A2 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2422625A1 (fr) 2000-09-19 2002-03-28 Bioexpertise, Llc Utilisation de la proteine de liaison de l'igf pour la sensibilisation selective de cellules cibles in vivo
EP2065038A1 (fr) 2007-11-30 2009-06-03 Pharnext Nouvelles approches thérapeutiques pour traiter la maladie de Charcot-Marie-Tooth
EP2135607A1 (fr) 2008-06-18 2009-12-23 Pharnext Combinaison de pilocarpine et methimazol pour le traitement de la maladie de Charcot-MarieTooth et des troubles associés
US9393241B2 (en) 2009-06-02 2016-07-19 Pharnext Compositions for treating CMT and related disorders
EP2263665A1 (fr) 2009-06-02 2010-12-22 Pharnext Nouvelles compositions pour traiter le CMT et troubles associés
BR112015030268B1 (pt) 2013-06-05 2023-01-31 Pharnext Composição farmacêutica
US10383870B2 (en) 2016-06-10 2019-08-20 Pharnext Early treatment of CMT disease
US11975041B2 (en) * 2017-11-20 2024-05-07 Novmetapharma Co., Ltd. Composition comprising CHP (cyclo-his pro) for preventing, improving or treating of bone loss related disease

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4818531A (en) * 1985-02-06 1989-04-04 Eli Lilly And Company Growth hormone and thyroid hormone
US5187151A (en) * 1991-02-12 1993-02-16 Genentech, Inc. Use of binding protein with igf-i as an anabolic growth promoting agent
US5310742A (en) * 1992-11-30 1994-05-10 Elias Alan N Uses for thioureylenes
WO1994009813A1 (fr) * 1992-10-29 1994-05-11 Genentech, Inc. Procede de traitement ou de prevention de l'obesite
US5527776A (en) * 1993-09-20 1996-06-18 Celtrix Pharmaceuticals Treatment of immunologic and hematologic disorders with IGFBP alone or complexed with IGF
WO1998036764A2 (fr) * 1997-02-25 1998-08-27 Celtrix Pharmaceuticals, Inc. Methode de traitement de troubles psychologiques et metaboliques par igf ou par igf/igfbp-3

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4818531A (en) * 1985-02-06 1989-04-04 Eli Lilly And Company Growth hormone and thyroid hormone
US5187151A (en) * 1991-02-12 1993-02-16 Genentech, Inc. Use of binding protein with igf-i as an anabolic growth promoting agent
WO1994009813A1 (fr) * 1992-10-29 1994-05-11 Genentech, Inc. Procede de traitement ou de prevention de l'obesite
US5310742A (en) * 1992-11-30 1994-05-10 Elias Alan N Uses for thioureylenes
US5527776A (en) * 1993-09-20 1996-06-18 Celtrix Pharmaceuticals Treatment of immunologic and hematologic disorders with IGFBP alone or complexed with IGF
WO1998036764A2 (fr) * 1997-02-25 1998-08-27 Celtrix Pharmaceuticals, Inc. Methode de traitement de troubles psychologiques et metaboliques par igf ou par igf/igfbp-3

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
AIZENMAN Y ET AL: "BRAIN NEURONS DEVELOP IN A SERUM AND GLIAL FREE ENVIRONMENT: EFFECTS OF TRANSFERRIN, INSULIN, INSULIN-LIKE GROWTH FACTOR-I AND THYROID HORMONE ON NEURONAL SURVIVAL, GROWTH AND DIFFERENTIATION", BRAIN RESEARCH,NL,AMSTERDAM, vol. 406, no. 1/02, 17 March 1987 (1987-03-17), pages 32 - 42, XP002046930, ISSN: 0006-8993 *
HUSSAIN M A ET AL: "INSULIN-LIKE GROWTH FACTOR I ALTERS PERIPHERAL THYROID HORMONE METABOLISM IN HUMANS: COMPARISON WITH GROWTH HORMONE", EUROPEAN JOURNAL OF ENDOCRINOLOGY,NO,SCANDINAVIAN UNIVERSITY PRESS, vol. 134, no. 5, 1 January 1996 (1996-01-01), pages 563 - 567, XP002072330, ISSN: 0804-4643 *
PASCASIO F M ET AL: "Methimazole in the treatment of hepato cellular carcinoma a pilot study", PHILIPPINE JOURNAL OF INTERNAL MEDICINE, vol. 19, no. 2, 1981, pages 80 - 84, XP000891564 *

Also Published As

Publication number Publication date
CA2345642A1 (fr) 2000-04-13
WO2000020024A2 (fr) 2000-04-13
AU6407099A (en) 2000-04-26
EP1117425A2 (fr) 2001-07-25
JP2002526417A (ja) 2002-08-20

Similar Documents

Publication Publication Date Title
HK1028033A1 (en) Sulfonamides for treatment of endothelin-mediated disorders.
HUP0103856A2 (hu) Gyógyszerkészítmény akut rendellenességek kezelésére
WO2001036365A3 (fr) Antagonistes recepteurs thyroidiens pour le traitement d'affections cardiaques et metaboliques
WO1998036764A3 (fr) Methode de traitement de troubles psychologiques et metaboliques par igf ou par igf/igfbp-3
AU7722600A (en) Compositions and methods for the diagnosis and treatment of immune disorders
WO1999017755A3 (fr) Medicaments
GB2333453A (en) Colostrinin and uses thereof
WO2001032926A3 (fr) Genes exprimes de maniere differentielle impliques dans l'angiogenese, polypeptides codes par lesdits genes, et techniques d'utilisation de ces genes
EP0824917A3 (fr) Utilisation d'un serotonine agoniste du 5-HT1F dans la fabrication d'un médicament pour le traitement ou l'amélioration du rhume ou de la rhinite allergique
WO1999024051A3 (fr) Utilisation d'antagonistes de la vasopressine pour le traitement de troubles ou de maladies de l'oreille interne
WO2000020024A3 (fr) Procedes pour traiter les troubles non thyroidiens
WO2000074710A3 (fr) Methodes de traitement du diabete
WO1999059617A3 (fr) Immunoregulateur
AU2001268422A1 (en) Agmatine and agmatine analogs in the treatment of epilepsy, seizure, and electroconvulsive disorders
AU3745795A (en) Use of CCK-B receptor antagonists for the treatment of sleepdisorders
WO1999048489A3 (fr) Methode permettant de retarder le declenchement de la maladie d'alzheimer et de traiter ou de retarder le declenchement d'autres maladies/troubles associes a l'amylose
EP0273310A3 (fr) 5-Aryl-3H-1,2,4-triazol-3-ones et leur emploi comme anticonvulsifs
CA2345353A1 (fr) Igf inactif aux fins du traitement du cancer
AU3600199A (en) A pharmaceutical composition containing ezrin mutated on tyrosine 353
WO2001053468A3 (fr) Enzymes du metabolisme lipidique (lme)
WO1999035169A3 (fr) Methodes et compositions permettant de traiter et de diagnostiquer les troubles lies a l'insuline
WO2000002877A3 (fr) Nouveaux composes pharmaceutiques
WO2001004090A3 (fr) Tetrahydro-isoquinolines et tetrahydrothienopyridines neurotrophiques, compositions et procedes associes
de Wit et al. To know or not to know: The psychological implications of presymptomatic DNA testing for autosomal dominant inheritable late onset disorders
WO2001064907A3 (fr) Enzymes metabolisant les lipides

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref country code: AU

Ref document number: 1999 64070

Kind code of ref document: A

Format of ref document f/p: F

AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 64070/99

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2345642

Country of ref document: CA

Ref country code: CA

Ref document number: 2345642

Kind code of ref document: A

Format of ref document f/p: F

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 573383

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1999951681

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1999951681

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1999951681

Country of ref document: EP